Raloxifene is a selective estrogen receptor modulator used for prevention and treatment of postmenopausal osteoporosis. It acts as an agonist of estrogen in bone but an antagonist in other tissues ...

Raloxifene can be classified as a second-generation SERM. A SERM interacts with estrogen receptors, functioning as an estrogen agonist in some tissues and an antagonist in other tissues.

Background: Both raloxifene and bisphosphonates are indicated for the prevention and treatment of postmenopausal osteoporosis, however these medications have different efficacy and safety profiles.

Although chronic kidney disease (CKD) is associated with an increased likelihood of osteoporosis, the efficacy and safety of therapies for osteoporosis in women with CKD remain unclear. Ishani et al.